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Robotic surgery for the management of gynecologic cancers allows for minimally invasive surgical removal of cancer-bearing
organs and tissues using sophisticated surgeon-manipulated, robotic surgical instrumentation. Early on, gynecologic oncologists
recognizedthatminimallyinvasivesurgerywasassociatedwithlesssurgicalmorbidityandthatitshortenedpostoperativerecovery.
Now, robotic surgery represents an eﬀective alternative to conventional laparotomy. Since its widespread adoption, minimally
invasive surgery has become an option not only for the morbidly obese but for women with gynecologic malignancy where
conventional laparotomy has been associated with signiﬁcant morbidity. As such, this paper considers indications for robotic
surgery,reﬂectsonoutcomesfrominitialroboticsurgicaloutcomesdata,reviewscosteﬃcacyandimplicationsinsurgicaltraining,
and discusses new roles for robotic surgery in gynecologic cancer management.
1.Introduction
Management of gynecologic cancer often involves surgery
followed by radiation, chemotherapy, or a combination of
both therapies. It is important for the gynecologic oncologist
to consider technical aspects of surgery as it pertains to a
patient’s goals for surgical intervention, planned extent of
surgical removal of cancer-bearing organs and tissues, a
patient’s postoperative speed of recovery, and how these
relate to the timing and administration of future anti-
cancer therapies. Techniques of minimally-invasive surgery,
initially involving laparoscopy and more recently robot-
assisted surgery, have emerged to address these consid-
erations [1–3]. Early on, gynecologic oncologists found
that laparoscopic surgery was associated with less surgical
morbidity and shortened postoperative recovery. Robotic
surgery has expanded the potential cohort of women capable
of undergoing minimally-invasive surgery, now cautiously
includingthemorbidlyobese,thoseinpoorhealth,andthose
having numerous comorbidities [4–7].
Early clinical successes of robotic surgery in the man-
agement of gynecologic cancers have prompted gynecologic
oncologists to consider this procedure more often. Here, we
discuss use of robotic surgery speciﬁcally for gynecologic
cancermanagement,focusingonits applications intheman-
agement of cervical, endometrial, and ovarian cancers.
2. Technical Aspects of Robotic Surgeryin
Gynecologic Cancer Management
Robotic surgery diﬀers substantially from laparoscopic sur-
gery in important ways. Conventional laparoscopy utilizes a
two-dimensional camera with images projected to monitors
positioned in proximity to the surgeon within the operating
room. Surgery is performed through 5-to-12-millimeter in-
cisions through which a camera and rigid instruments are
placed through abdominal ports and controlled directly by
the surgeon at the surgical bedside. Commonly listed limita-
tions to conventional laparoscopy are diﬃculty in manipu-
lating the instruments and collapsed two-dimensional optics2 Obstetrics and Gynecology International
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Figure 1: Robotics in gynecologic cancer surgery. (a) Depicted is a da Vinci robotic surgical platform used at University Hospitals of
Cleveland (Cleveland, Ohio). (b) With the patient in dorsal lithotomy position and with the robot docked between the legs, an initial
12-millimeter (mm) port incision is made 40mm cephalad to the umbilicus. Additional 8-millimeter port incisions are made following a
conventional triangle arrangement. A 12-millimeter instrument port for an assistant is also made as indicated. Stereoscopic optics in the
surgeon control console allows for three-dimensional viewing of the surgical ﬁeld (not shown).
rendering complex tasks associated with more radical pelvic
surgery arduous. While an experienced laparoscopic surgeon
may be able to accomplish radical hysterectomy with or
without lymphadenectomy using laparoscopic instrumenta-
tion, the nontraditional skills and unfamiliarity with two-
dimensional optics needed for laparoscopy have led to in-
frequent use of a laparoscopic approach by gynecologic
oncologists [8]. As such, the number of patients beneﬁt-
ting from a minimally-invasive procedure to manage their
gynecologic cancer is low. With the introduction of robotics,
many of the frustrations and limitations of inexperienced
laparoscopic surgeons have been minimized due to the
improvementinergonomicsinherentintheroboticplatform
[4–23]. Using a robotic platform to perform surgery allows
the primary surgeon to control surgical instruments (i.e., up
to three surgical instrument arms plus camera) in a “hands-
oﬀ” manner (Figure 1). Moreover, the surgical instruments
have greater range of motion than conventional laparo-
scopic instrumentation, allowing “wristed action” rotation
of instruments and motion scaling. Improved optics allow
three-dimensional view of the surgical ﬁeld. These technical
aspects of robotic surgery have advantages of speeding
learning new surgical skills by the surgeon and translating
and adapting their own surgical skills to the robotic surgery
platform. Descriptions of various robotic-assisted surgical
techniques are referenced for the reader [4–23].
Robotic surgery platforms have evolved from the initial
telesurgery units perfected for the military [3]t ov o i c e -
operated laparoscopy such as the automated endoscopic sys-
tem for optimal positioning (AESOP, Computer Motion Inc.
[Goleta, Calif]) [4, 9] to robotic platforms. The two most
commonroboticplatformsaretheZEUS(ComputerMotion
Inc. [Goleta, Calif]) [10] and the da Vinci (Intuitive Surgical,
Inc. [Sunnyvale, Calif]) [11] systems. Both of the robotic
platforms position the gynecologic oncologist at a console
remote from the patient undergoing surgery. Although the
surgeon is no longer at the bedside, the three-dimensional
optics, dexterity provided by wrist-like instrument rotation,
reduction in surgeon hand tremor, and motion scaling have
peaked interest among gynecologic oncologists to do cancer
surgeries on a minimally-invasive robotic device. As an
example, Figure 1 provides an example of the da Vinci ro-
botic surgery platform in use at University Hospitals of
Cleveland (Cleveland, Ohio).
3. Robotic Surgery for Cervical Cancer
For many gynecologic oncologists, it remains an open ques-
tionwhetherrobotic-assistedminimally-invasivesurgerycan
besubstitutedforconventionallaparotomyinallgynecologic
cancer patients. Outside of clinical trials, consideration for
goals of surgical intervention, patient recovery, and adequate
assessment of risk factors for local or distant recurrence
is needed. From available data in cervical cancer patients
(Table 1), robotic surgery appears to provide suﬃcient
surgery to assess pathologic tumor size, tumor grade, deep
cervix organ invasion, lymphovascular invasion, cancerous
lymph node status, and cancer-free margins of resection
without undue risk of intraoperative injury. For this dis-
cussion here, a comprehensive surgicopathological staging
procedure comprised removal of the uterus and ovaries,
adnexa, and any number of lymph nodes. Such a proce-
dure was achieved in the majority of patients undergoingObstetrics and Gynecology International 3
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robot-assisted surgeries (Table 1). As the basis of adjuvant
radiation and chemotherapy recommendations are founded
in surgicopathological parameters, gynecologic oncologists
who perform robot-assisted radical hysterectomy for cervical
cancer must ensure that their robotic surgery continues to
provide this informative data.
Experiences with robotic surgery to perform radi-
cal hysterectomy in patients with early stage cervical cancer
have demonstrated feasibility and safety of the technique
(Table 1). Blood loss secondary to cutting and extirpation of
theuterusandcervixappearsminimalwhenperformingrad-
ical hysterectomy for cervical cancer. Patient in-room opera-
tive times are longer than a conventional approach; however
operative times do decrease with increasing familiarity and
robotic skill. To date, robotic and laparoscopic procedures
are associated with fewer lymphocysts, lymphoceles, postop-
erative infections, and ileus [12–15]. This has contributed to
awidespreadadoptionofroboticsurgeryinthemanagement
of women with early cervical cancer. Since improved cervical
cancer screening has led to the earlier detection of organ-
conﬁned disease, it is likely that minimally-invasive robotic
surgery will become more commonplace in the management
of early-stage cervical cancer.
Clinical use of robotic surgery for management of more
bulky (>4cm) cervical cancer remains sparse (Table 1).
Moreover, there are no randomized studies evaluating
robotic surgeries compared to laparoscopy-assisted surgeries
or conventional laparotomy. Initial case experience for early-
stage cervical cancer is encouraging. However, caution is
warrantedastherehavenotyetbeensuﬃcientstudiesofport
and operative site relapse rates (Table 1). Further study is on-
going to assess these important questions.
4. Robotic Surgery for Endometrial Cancer
Gynecologic oncologists were quick to recognize the advan-
tages of robotic-assisted surgery in women with endometrial
cancer. Initial studies praised ease of surgical technique, ade-
quacyofsurgicalspecimensforcancerstaging,andreduction
in patient hospital stay and time to recovery [8, 16–20]. One
particular advantage of the robotic platform was surgical
conﬁdence in adequate lymphadenectomy (i.e., >4l y m p h
nodes retrieved from right and left pelvis and para-aortic
node-bearing tissues) without undue risk of injury to pelvic
organs and blood vessels ([8, 16–20], Table 2).
Consensus deﬁnitions of adequacy of cancer-staging
surgery remain debatable. Endometrial cancer data have in-
dicated that high tumor grade, deep myometrial invasion,
involvement of the cervix, lymphovascular invasion, and
presence of malignant lymph nodes, all contribute to ad-
juvant treatment recommendations [24]. There has been
no indication that robotic surgery limits these assessments
(Table 2). An important retrospective study comparing
robotic-assisted surgery and conventional surgery backs this
claim [8]. Of 275 women undergoing minimally-invasive
total hysterectomy and pelvic and para-aortic lymphadenec-
tomy, 102 underwent robotic-assisted and 173 underwent
conventional laparoscopic cancer-staging surgeries. Surgery
performed did not bias cancer grading or tumor type,
number of lymph nodes retrieved from the pelvis or para-
aortictissues,orexciseduterineweight.Intraoperativeinjury
rates were similar (2.0% robotic versus 3.5% laparoscopic,
P = 0.71).Therewerealsonosubstantialtrendsinprolonged
hospital stay (1.9 days versus 2.3 days, P = 0.09) or re-
quirement of second surgery (e.g., small bowel perforation
or repair of vaginal apex dehiscence, 1.9% versus 1.2%)
after robotic or conventional surgery, respectively. Overall,
robotic-assisted surgeries were deemed safe and comparable
to laparoscopic surgeries. While these results are impressive,
this study consisted of cases done by a single surgeon at a
single academic practice dedicated to improving minimally-
invasive surgical techniques, introducing substantial selec-
tion and performance bias. Over multiple studies, there has
been a trend for more vaginal apex dehiscence in women
undergoing robotic-assisted surgical procedures, with rates
of 2.9% after robotic and 2.4% after conventional surgery
[16–20]. In addition, rates of procedure conversion from
robot assisted to laparotomy have ranged between 4% and
15%[16–20].Dedicatedmulti-institutionalstudyofrobotic-
assistedsurgicalapproachesforendometrialcancerisneeded
so that over- or underestimates of appropriateness of cancer
staging,surgicalcomplications,andoperativeandpatientre-
covery time are more relevant to practicing gynecologic
oncologists.
Moreover, it is important for the gynecologic oncologist
to recognize that surgery in the morbidly obese presents a
unique surgical challenge. Not only are these patients more
susceptible to postoperative complications such as poor
wound healing, but their body mass often makes the sur-
gical procedure technically more challenging whether the
approach is laparoscopic or open. Many feel that the ad-
vantages of a robotic platform help overcome some of
the barriers to operating on the morbidly obese with en-
dometrial cancer. To date, few papers have addressed the use
of robotic surgery speciﬁcally in the obese population. The
limited data to date has shown that increased body mass
index is not generally associated with greater complications
inroboticstagingforendometrialcancer[25].Arandomized
study conducted by the Gynecologic Oncology Group (LAP-
2) comparing laparoscopy and laparotomy showed no sub-
stantial diﬀerences in oncologic assessment or outcome with
laparoscopy,buttherewereincreasedoddsofnotsuccessfully
completing laparoscopy without conversion to laparotomy
in the obese (odds ratio: 1.11, 95% conﬁdence interval
1.09 to 1.13) [26]. While it remains controversial to use
robotic-assisted procedures in the obese, it has been shown
that surgical intervention followed by adjuvant therapy
successfully manages pelvis-conﬁned endometrial cancer in
the morbidly obese [27, 28]. Indeed, these studies indicate
that the morbidly obese patient does not often have cancer
limit life expectancy, but rather comorbidities resulting from
obesity contribute to mortality. Robotic surgical techniques
that limit confounding surgical morbidity in the obese may
be of interest to the gynecologic oncologist. Further surgical
development of robotic-assisted instrumentation for the
o b e s ei se x p e c t e d .Obstetrics and Gynecology International 5
5. Robotic Surgery for OvarianCancer
Management of epithelial ovarian cancer is predicated upon
optimal cytoreductive surgery, with less than 1cm of re-
sidual disease. Recurrence and overall survival improves
with further cytoreduction incrementally, with microscopic
residual disease followed a platinum-taxane combination
chemotherapyinfusion[29]resultsinthegreatestoveralland
progression-free survival. Most commonly ovarian cancer
is identiﬁed at an advanced stage often requiring radical
surgical procedures to achieve “optimal” status. Minimally-
invasive surgeries for maximal cytoreduction of ovarian can-
cers have been attempted since the 1990s. Whether robotic-
assisted surgery improves upon the ability to surgically cy-
toreduce ovarian cancer is an open question. While the
improved ergonomics may aid in these type radical surgery,
other limitations inherent in the robotic platform—namely
the inability to simultaneously operate in the pelvis and
abdomen—remain a signiﬁcant disadvantage.
Robotic surgery for ovarian cancer management remains
relatively untested (Table 3). In the limited experience to
date, blood loss and postoperative complications of bowel
injury and wound dehiscence are infrequent (Table 3).
Port site relapses have not been reported routinely among
the early investigational studies. A single manuscript has
compared robotic surgery to traditional means of ovarian
cancer staging surgery. In this case control study, 25 patients
undergoing primary staging for epithelial ovarian cancers
were compared to similar patients treated by laparoscopy
and laparotomy. The authors concluded that laparoscopic or
robotic surgery is reasonable approach for primary tumor
excision in patients with ovarian cancers. It must be empha-
sized that these patients were highly selected and their results
are not likely to apply to all patients with ovarian cancer. The
authorsthemselvesnotedthatforpatientswithadvanceddis-
ease requiring multiple complicated additional procedures,
laparotomy remains the optimal surgical approach [23].
Clinical trials have demonstrated that intraperitoneal
routes of chemotherapy administration should be strongly
considered for treatment of women with intrabdominal
spread of ovarian cancer. While one advantage of robotic
surgery is that postoperative surgery-related complications
and patient recovery time may be reduced, reducing wait
time for chemotherapy, the technique may present a critical
shortcoming in that the port sites for the robotic surgical
instruments may be seeded with tumor. While this has yet
to be rigorously investigated, concerns that eﬀectiveness of
intraperitonealandintravenouschemotherapiesmaybelow-
ered due to this phenomena. To this end, the use of robotic
surgery in the setting of ovarian cancer management is not
recommended until further study suggests otherwise.
6.RoboticSurgeryinAnticipationof
Radiation Therapy
Most often, surgery for gynecologic malignancies involves
removal of pelvic organs in the female reproductive sys-
tem precluding subsequent pregnancy. However, there are
clinical situations such as adolescent female lymphoma or
cervical cancer in which fertility-sparing surgery and tumor-
directed radiation may be considered [25, 29–35]. To shield
the ovaries from irradiation, an oophoropexy or ovarian
transposition may be performed either laparoscopically or
robotically. Here, minimally-invasive robotic surgery may
play a role as demonstrated in cases of cervical cancer man-
agement. Transposition of the ovaries to midline or to lateral
iliac wings, depending on the radiotherapeutic target, results
in radiation dose to the ovaries of 4% to 8% of the pelvic
radiation dose [36–39]. When done, ovarian position should
be marked with surgical clips that can be identiﬁed on
radiation therapy imaging. While ideal surgical removal of
gynecologic cancers will often limit such a role for robotic
surgery, the ability of robotic surgery to preserve fertility
should not be overlooked when radiation therapy may be
contemplated.
7. Trainingof SurgeonsinRobotic Surgery
Hysterectomy and gynecologic organ surgery are among
the most common services surgeons provide for American
women besides cesarean delivery [40]. When surveyed, sur-
geons have increased their use of robotic-assisted procedures
from 10% in January 2008, to 40% in February 2011 ac-
cording to one source [41]. Such a trend implies that
surgical training in robotic surgery become in line with
other fundamental aspects of surgical residency, and perhaps
because of its perceived importance by patients, a skill
demanded for maintenance of surgical certiﬁcation. To this
end, an eﬀective platform for teaching this skill may hinge
upon didactic symposia and clinical dry laboratory practice.
A robotic platform improves positional ergonomics and
visualization for training physicians except perhaps among
the most experienced laparoscopic surgeons. Surgical oper-
ating room time and eﬀort by the surgeon decreases over
time and with gained experience. It has been suggested that
12casesareneededbyasurgeonandancillarystaﬀtodevelop
the orchestrated eﬀort for facile robotic surgery—operating
room times dropped from a mean of 410 minutes for the
ﬁrst 12 robot-assisted cases to a mean of 337 minutes for
the next consecutive 12 robot-assisted cases in one series
[41]. Such data argue for a dedicated hospital-based surgical
robotics team to reduce operative time, global room time,
and(non)renewableresources.Moreover,trainingofsurgical
residents and inexperienced surgeons in the techniques of
robotics may protract both operative and global room time
in some instances, but the overreaching goal of mastering
a surgical skill demanded in their future practice mandates
patience at the console by the learned surgeon during such
instruction.
More measures for mastery of robotic skill include (a)
complexity of surgical case undertaken with robotics and
(b) conversion rates from robotics to laparotomy. A surgical
training beginning point for pelvic robotic surgery may be
the performance of a hysterectomy, which must be learned
from abdominal, vaginal, and laparoscopic approaches.
Adding a robotic-assisted approach to the learning surgeon’s6 Obstetrics and Gynecology International
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repertoireseemsalogicalﬁrststep.Inoneprogram,surgeons
newtoroboticsurgeryhadasteeplearningcurveforrobotic-
assisted suturing of the vagina, where mean robot console
times of 326 seconds versus a mean laparoscopic suturing
time of 382 seconds was observed among 12 residents in
training [41]. Data are still emerging regarding the com-
plexity of surgical care provided by robotic platforms. Con-
version rates from robotics to laparotomy range from 3% to
12%, doing so for a multitude of unspeciﬁed reasons in most
series [15, 41, 42].
Lawful cause of action claims against a surgeon for in-
suﬃcient training or credentialing and lack of patient in-
formed robotic surgical consent have been ﬁled [43]. For
many surgeons currently in practice, robotic surgery devel-
oped after completing their residency training. The practi-
tioner must appreciate that to counsel a woman on robotic
surgery, one must be intimately familiar with the inherent
hazards of a planned robotic surgery. Indeed, prior patient
knowledge both on a surgeon’s familiarity and performance
of robotic surgery and the intrinsic complications that may
arise from a robotic surgery approach may aﬀect a woman’s
decision to undergo a robotic-assisted surgery. This is not
to imply that procedural hazards do not arise more or less
with any particular surgical approach, but rather it is to
bring attention to physician duty to inform a woman about
anticipated risks and mitigation of risks during a robotic-
assistedsurgery.Itiscriticalthatthelegalpitfallsarisingfrom
insuﬃcient training, credentialing, and informed consent
should be addressed [43].
8. Robotic Surgery Costs for
Oncologic Procedures
Robot-assisted gynecologic surgery costs more than con-
ventional laparoscopic procedures [44]. Publications on the
cost eﬀectiveness of oncologic robotic surgery do not yet
include persuasive and informative ﬁnancial data supporting
or refuting robotic-assisted procedure. In a single American
institutioncostreviewofconsumables,operatingroomtime,
and anesthesia time [41], it was found that a robotic hys-
terectomy cost of $18,570 (US$) was billed compared to
a laparoscopic hysterectomy cost of $13,867 (US$). Capital
investment in a robotic surgery platform was not accounted
for in this analysis. Consider that the price tag for a robotic
platform ranges from $1.2 to $1.5 million US dollars and
comes with a yearly maintenance fee of $138,000 (US$).
Indeed, the use of robotics may be more expensive in cur-
rent dollars than performing the same procedure either
by laparoscopy or even by laparotomy. And yet, “cost sav-
ings” are created by an oﬀset of reduced hospitalization
and resources, lower costs associated with management of
resultant surgical morbidity, and earlier patient return to the
workforce. Data remain immature for full comment. Finan-
cial impacts of robotic surgery for oncologic procedures are
active arenas for health and marketing research.
Implementing a robotics program for oncology services
in tertiary cancer centers may not give the chance to initiate a
program with undemanding cases.A shift from conventional
laparotomy and laparoscopy to robotic-assisted procedures
maybetimeconsumingandultimatelylimitedbyasurgeon’s
ability and ﬂexibility to reserve additional operating room
time.Anticipatedrevenuestreamsmayneedtobeconsidered
adaptive until surgeon and staﬀ eﬃciency peaks. Quality of
life outcomes on the economic impact of robotic-assisted
surgery are awaited.
9. Expert Commentary and Conclusion
Despite the encouraging early results suggesting minimally-
invasiveroboticsurgeryforwomenwithgynecologiccancers,
questions remain about the surgical eﬀectiveness of this
approach.Insmallclinicalstudies,roboticsurgeryhasshown
promising results of reduced morbidity. Further study of
robotic surgery technical parameters is needed prior to
widespread clinical application of robotic surgery in the
management of gynecologic cancers. Training programs are
now in place. While it is important to investigate alternative
means of surgery with high precision, it remains unclear
whether robotic surgery can oﬀer the same therapeutic ef-
ﬁcacy as laparotomy. Moreover, cost analyses of robotic-
assisted surgery versus other surgery are underway. Both en-
thusiasm and restraint are appropriate in interpreting
available robotic surgery data for treatment of gynecologic
cancers. In the end, randomized data will be needed to
better assess the oncologic outcome of robotic surgery for
gynecologic malignancy.
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